...
首页> 外文期刊>Molecular cancer research: MCR >Expression of Wnt3 activates Wnt/β-catenin pathway and promotes EMT-like phenotype in trastuzumab-resistant HER2-overexpressing breast cancer cells
【24h】

Expression of Wnt3 activates Wnt/β-catenin pathway and promotes EMT-like phenotype in trastuzumab-resistant HER2-overexpressing breast cancer cells

机译:Wnt3的表达激活了Wnt /β-catenin通路并促进了曲妥珠单抗耐药的HER2过表达的乳腺癌细胞中的EMT样表型

获取原文
获取原文并翻译 | 示例
           

摘要

To understand the mechanisms leading to trastuzumab resistance in HER2-overexpressing breast tumors, we created trastuzumab-insensitive cell lines (SKBR3/100-8 and BT474/100-2). The cell lines maintain HER2 receptor overexpression and show increase in EGF receptor (EGFR). Upon trastuzumab treatment, SKBR3/100-8 and BT474/100-2 cell lines displayed increased growth rate and invasiveness. The trastuzumab resistance in SKBR3/100-8 and BT474/100-2 was accompanied with activation of the Wnt/β-catenin signaling pathway. Further investigation found that Wnt3 overexpression played a key role toward the development of trastuzumab resistance. The expression of Wnt3 in trastuzumab-resistant cells increased nuclear expression of β-catenin and transactivated expression of EGFR. The increased Wnt3 in the trastuzumab-resistant cells also promoted a partial EMT-like transition (epithelial-to-mesenchymal transition); increased N-cadherin, Twist, Slug; and decreased E-cadherin. Knockdown of Wnt3 by siRNA restored cytoplasmic expression of β-catenin and decreased EGFR expression in trastuzumab-resistant cells. Furthermore, the EMT markers were decreased, E-cadherin was increased, and the cell invasiveness was inhibited in response to the Wnt3 downregulation. Conversely, SKBR3 cells which had been stably transfected with full-length Wnt3 exhibited EMT-like transition. The Wnt3 transfectants, SKBR3/Wnt3-7 and SKBR3/Wnt3-9, showed a significant decrease in E-cadherin and increase in N-cadherin, Twist, and Slug. The cells were less sensitive to trastuzumab than parental SKBR3 and vector-transfected cells. In summary, our data suggest that Wnt3 overexpression activates Wnt/β-catenin signaling pathway that leads to transactivation of EGFR and promotes EMT-like transition. This could be an important mechanism leading to trastuzumab resistance in HER2-overexpressing breast cancer cells.
机译:为了了解在过表达HER2的乳腺肿瘤中导致曲妥珠单抗耐药的机制,我们创建了曲妥珠单抗不敏感细胞系(SKBR3 / 100-8和BT474 / 100-2)。细胞系维持HER2受体过表达,并显示EGF受体(EGFR)增加。经曲妥珠单抗治疗后,SKBR3 / 100-8和BT474 / 100-2细胞系显示出增加的生长速率和侵袭性。 SKBR3 / 100-8和BT474 / 100-2中的曲妥珠单抗耐药性伴随Wnt /β-catenin信号通路的激活。进一步的研究发现,Wnt3的过表达在曲妥珠单抗耐药的发生中起着关键作用。 Wnt3在曲妥珠单抗耐药细胞中的表达增加了β-catenin的核表达和EGFR的反式表达。曲妥珠单抗耐药细胞中Wnt3的增加也促进了部分EMT样转变(上皮到间充质转变)。 N-钙黏着蛋白,扭曲,弹头增加;和减少的E-cadherin。 siRNA敲低Wnt3可恢复曲妥珠单抗耐药细胞的β-catenin细胞质表达,并降低EGFR表达。此外,响应于Wnt3的下调,EMT标记降低,E-钙黏着蛋白增加,并且细胞侵袭被抑制。相反,已被全长Wnt3稳定转染的SKBR3细胞表现出EMT样的转变。 Wnt3转染子SKBR3 / Wnt3-7和SKBR3 / Wnt3-9显示E-钙粘着蛋白显着降低,N-钙粘着蛋白,Twist和Slug升高。该细胞对曲妥珠单抗的敏感性低于亲代SKBR3和载体转染的细胞。总而言之,我们的数据表明Wnt3过表达激活Wnt /β-catenin信号传导途径,从而导致EGFR的反式激活并促进类似EMT的转变。这可能是导致过表达HER2的乳腺癌细胞中曲妥珠单抗耐药的重要机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号